Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction

Int J Dermatol. 2023 Oct;62(10):1292-1294. doi: 10.1111/ijd.16572. Epub 2023 Jan 11.

Authors

Connie R Shi¹, Michael Shaughnessy², Kartik Sehgal³, John R Clark⁴, Kerry L Reynolds⁴, Jennifer Toyohara⁵, Steven T Chen²

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
² Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
³ Department of Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
⁴ Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
⁵ Adult & Pediatric Dermatology, PC, Concord, MA, USA.

PMID: 36628976
DOI: 10.1111/ijd.16572

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Exanthema*
Humans
Stevens-Johnson Syndrome* / diagnosis
Stevens-Johnson Syndrome* / drug therapy
Stevens-Johnson Syndrome* / etiology

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized

Grants and funding

Dermatology Foundation